PROTAC technology offers hope for treating castration-resistant prostate cancer. Download PDF Copy; Reviewed. Compuscript Ltd Jan 30 2025. Announcing a new publication for Acta Materia Medica journal.

SignalChem Biotech supports research into new PROTAC®-based therapies by offering a diverse array of ubiquitin enzymes, including CRBN/DDB1/Cul4A/Rbx1 complexes, E1 activating enzymes, E2 conjugating ...

PROTAC technology for prostate cancer treatment. Compuscript Ltd. Journal Acta Materia Medica DOI 10.15212/AMM-2024-0075 ...

The company's proprietary PROTAC® (PROteolysis TArgeting Chimera) technology platform aims to harness the body's natural protein disposal system to selectively degrade disease-causing proteins.

What Is PROTAC Technology? Proteolytic targeting chimera (PROTAC) is a new type of drug design technology that works by inducing the degradation of target proteins. Unlike conventional small molecules ...

Arvinas utilizes PROTAC technology to develop protein degraders, with vepdegestrant as a lead drug candidate in Phase 3 studies. Vepdegestrat will read out data from a large, late-stage study in ...

In addition, Arvinas' PROTAC technology has a flexible and modular design that allows for rapid optimization and customization of the molecules for different targets and indications.

Oerth's unique PROTAC® protein degradation technology is expected to be a new, game-changing generation of more sustainable crop protection products / The agreement recommits to the combination ...

Ubiquitins are essential proteins that regulate cellular functions by marking other proteins for degradation, thereby maintaining homeostasis. Targeted Protein Degradation (TPD) leverages this ...